Last reviewed · How we verify
NCT06575647: VET
Vivax Elimination With Tafenoquine (VET) Study
Phase 4 trial testing Tafenoquine in Malaria in 1,242 participants. Completed in 4 October 2025.
4 October 2025
Quick facts
| Lead sponsor | Shoklo Malaria Research Unit |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,242 |
| Start date | 19 February 2025 |
| Primary completion | 4 October 2025 |
| Estimated completion | 4 October 2025 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Tafenoquine (TAFENOQUINE) — full drug profile →
Conditions studied
- Malaria — all drugs for Malaria →
- Malaria, Vivax — all drugs for Malaria, Vivax →
- Plasmodium Vivax — all drugs for Plasmodium Vivax →
- Plasmodium Vivax Malaria — all drugs for Plasmodium Vivax Malaria →
Sponsor
Shoklo Malaria Research Unit — full company profile →
Who can join
6 Months and older, any sex, with Malaria or Malaria, Vivax. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Theoretically, so long as there is a sink-source for malaria, transmission could be sustained at very low level (even at sub-microscopic oscillation) and reintroduce malaria either as sporadic cases or as resurgent outbreak. Uncertainty or shortage in financing has typically limited the malaria control or elimination projects to go further beyond the "Pre-elimination phase". Since malaria is no longer a top scoring mortality in national statistics in South East Asia, the governments/stakeholders are less willing to allocate from the austerity budget. There are proven evidence of resurgences after cessation of intervention programs where over 90% of all resurgence events were attributed to the interruption of malaria control programmes. In Karen state Myanmar-Thailand border, multiple factors including a cascade of political, financial, and logistical fiascos have compounded on the ongoing malaria elimination activities. Deleterious impacts after military coup since 2021 February including cessation of foreign investment, humanitarian aids, Civil Dis-obedience Movement of government staff and resuming armed-conflicts have strained the nearly failed health infrastructure of the country to a collapse stage. Interruption of the National Malaria Control activities due to the health system failure and accelerating combats countrywide could inevitably lead to the overturn in recently achieved malaria pre-elimination status especially in Karen state. The disruption in health services within Myanmar is already resulting in an increase in malaria. Supply of the first line antimalarial drug artemether-lumefantrine, and other essential malaria control interventions, has been interrupted. The study is proposed to evaluate the impact of Mass Drug Administration (MDA) in 3 villages in Karen state with consistently high incidence of P. vivax and spatially clustered within 5 km radius. This proposal outlines a study to assess the feasibility and the safety of tafenoquine MDA.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Evolving Landscape of Malaria Prevention Strategies: A Review of Recent Developments
Charavanamuttu Y, Agyeman Wamba A, Taylor-Robinson A, Lampejo T. · · 2026
Verify or expand the search:
- PubMed search for NCT06575647
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tafenoquine
Trials testing the same drug.
- NCT06666491 — An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken · Phase 3 · recruiting
- NCT04704999 — Southeast Asia Dose Optimization of Tafenoquine · Phase 4 · recruiting
- NCT06207370 — Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis · Phase 2 · recruiting
- NCT06148792 — A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria · Phase 3 · recruiting
- NCT04984759 — Tafenoquine and Primaquine in Colostrum and Breast Milk · Phase 4 · withdrawn
Other recruiting trials for Malaria
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
- NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
- NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
- NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting
Other Shoklo Malaria Research Unit trials
Trials by the same sponsor.
- NCT05788094 — ACT vs CQ With Tafenoquine for P. Vivax Mono-infection · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06575647 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shoklo Malaria Research Unit
- Last refreshed: 6 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06575647.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing